@article{963d9945051040489a3bf4c4f9831e54,
title = "Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies",
abstract = "Objectives: To identify factors limiting and facilitating patient-centered communication (PCC) in the United States hematology-oncology setting, with a focus on multiple myeloma (MM), given the limited attention to PCC and rapid pace of change that has taken place in this setting. Methods: A literature search was performed from 2007 to 2017 to identify published articles and congress abstracts related to clinician-patient communication and treatment decision-making in oncology. Search results were evaluated by year of publication and disease area. A thematic assessment was performed to identify factors limiting and promoting PCC for patients with MM and other hematologic malignancies. Results: Of the 6673 publications initially retrieved, 18 exclusively reported findings in patients with hematologic malignancies and were included in this review. We identified three critical, but modifiable, barriers to PCC in the hematologic malignancy setting, including insufficient information exchange, treatment goal misalignment, and discordant role preferences in treatment decision-making. Factors that enhanced interaction quality included educational programs for clinicians and patients. Conclusions: Patients with MM and other hematologic malignancies experience a distinct set of challenges that may affect PCC. Practice Implications: Clinicians have the opportunity to improve patient care by proactively addressing the identified barriers and implementing strategies demonstrated to improve PCC.",
keywords = "Communication, Decision-making, Hematologic malignancy, Multiple myeloma, Patient care",
author = "LeBlanc, {Thomas W.} and Baile, {Walter F.} and Susan Eggly and Bylund, {Carma L.} and Sandra Kurtin and Monica Khurana and Rani Najdi and Julie Blaedel and Wolf, {Jeffrey L.} and Rafael Fonseca",
note = "Funding Information: This work was supported by Amgen Inc . Funding Information: TWL has received consulting fees from CareVive, Flatiron, Otsuka, Pfizer, Seattle Genetics, and Welvie; has received research funding from AstraZeneca and Seattle Genetics; has received honoraria from Amgen, Agios, AbbVie, Celgene, Helsinn, Heron, Otsuka, and Medtronic; grants or other funding include a Cambia Health Foundation Sojourns Scholars Award and American Cancer Society Mentored Research Scholar Grant. WFB has received consulting fees from Amgen. SE has received consulting fees and has served on advisory committees for Amgen. CLB is an employee of the University of Florida; has received consulting fees from the Leukemia and Lymphoma Society, Amgen, and Memorial Sloan-Kettering Cancer Center; has received honoraria from Hamad Medical Corporation (Doha, Qatar). SK has received consulting fees from Celgene, Amgen, and Takeda. MK is an employee of Amgen. RN and JB are employees of, and own stock in, Amgen. JLW has received consulting fees from Amgen, Takeda, Celgene, Novartis, Janssen, and Adaptive. RF has received consulting fees from Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Pharmacyclics, Merck, Sanofi, Kite and Juno; has served on scientific advisory boards for Adaptive Biotechnologies; holds a patent with the Mayo Clinic for prognosticating myeloma using fluorescence in situ hybridization. Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",
year = "2019",
month = sep,
doi = "10.1016/j.pec.2019.04.028",
language = "English (US)",
volume = "102",
pages = "1602--1612",
journal = "Patient Education and Counseling",
issn = "0738-3991",
publisher = "Elsevier Ireland Ltd",
number = "9",
}